Depression & Anxiety

When Antidepressants Stop Working

Major depressive disorder affects hundreds of millions of people worldwide, yet the standard-of-care treatment — SSRIs and SNRIs — provides meaningful relief for only about 40-50% of patients. For those with treatment-resistant depression (TRD), defined as depression that hasn’t responded to at least two different antidepressant trials, the options have historically been grim: higher doses, combination medications, electroconvulsive therapy, or simply learning to live with it.

The same pattern holds for anxiety disorders. Benzodiazepines provide short-term relief but create dependency. SSRIs help some people but take weeks to work and often come with significant side effects. Many people cycle through multiple medications for years without finding adequate relief.

Ibogaine and 5-MeO-DMT offer a genuinely different mechanism — one that doesn’t just modulate serotonin or GABA, but appears to reset the brain’s overall regulatory function.

How Ibogaine Affects Depression Neurologically

Depression involves dysregulation across multiple neurotransmitter systems — not just serotonin. Ibogaine acts on serotonin, dopamine, glutamate, and sigma receptors simultaneously, producing a broad neurochemical reset that goes far beyond what any single antidepressant can achieve.

Perhaps more importantly, ibogaine significantly upregulates BDNF (Brain-Derived Neurotrophic Factor) and GDNF — neurotrophic growth factors that promote the growth and maintenance of neurons. Depression is associated with reduced neuroplasticity and even neuronal atrophy in the hippocampus. By stimulating neuroplasticity, ibogaine may literally help rebuild the neural substrate of mood regulation.

The Stanford study — which used veterans with traumatic brain injury and PTSD, not people with depression alone — reported an average 87% reduction in depression scores at one month (Cherian et al., Nature Medicine, 2024 — observational, open-label, n=30, no control group; the paper reports the effect size, d=2.80). For pure treatment-resistant depression, the clinical evidence base is smaller but consistently promising.

5-MeO-DMT: The Anxiety Reset

Anxiety at its core is the nervous system stuck in threat-detection mode. The default mode network — the brain’s self-referential processing loop — runs hot in anxiety, generating an almost constant stream of future-oriented worry and rumination.

5-MeO-DMT briefly and powerfully disrupts the default mode network. During the 15-45 minute experience, the sense of a separate “self” that is anxious about the future temporarily dissolves. What most people find waiting on the other side of that dissolution is a profound stillness — an experience of the present moment that is free from anxiety by definition.

Many people with anxiety disorders describe a lasting shift in their relationship to anxious thoughts after 5-MeO-DMT: rather than being swept away by them, they notice them from a slight distance. This is precisely what years of meditation practice aims to cultivate — and 5-MeO-DMT can catalyze it in a single session.

“I’d been on four different antidepressants over eight years. Two weeks after ibogaine and 5-MeO-DMT I started laughing again — just spontaneously laughing at things. My family didn’t know what to make of it.” — Psychedelic Connect patient, Chicago

Treatment Protocol for Depression & Anxiety

For people seeking ibogaine primarily for depression and anxiety (rather than addiction), the protocol differs slightly:

• A thorough psychiatric screening to assess appropriateness and identify contraindications
• A medication review and tapering plan — SSRIs and SNRIs must be stopped 2–4 weeks before treatment
• The ibogaine session itself (18–36 hours) — often described as a psychologically intense life review
• 5-MeO-DMT the following day for deeper integration
• A post-treatment integration period, ideally with a psychedelic-informed therapist

Many depression and anxiety patients choose an extended stay (7–14 days) at the clinic to allow for initial integration in a supported, beautiful environment before returning to normal life.

For the ibogaine-specific evidence on mood, see ibogaine for depression.

Who Is a Good Candidate?

Ibogaine and 5-MeO-DMT for depression and anxiety are generally most appropriate for people who:

• Have tried at least two antidepressants without adequate response (treatment-resistant depression)
• Are willing to taper off current medications before treatment
• Do not have active psychosis, mania, or certain cardiovascular conditions
• Are psychologically prepared for an intense inner experience
• Have a plan for integration and ongoing support after treatment

5-MeO-DMT alone (without ibogaine) may be appropriate for some anxiety cases where addiction is not present and the person is primarily seeking a consciousness reset. Our partner clinics offer both combined and standalone protocols.